New Biomarkers to Define A Biological Borderline Situation for Pancreatic Adenocarcinoma – Results of An Ancillary Study of the PANACHE01-PRODIGE48 Trial

To investigate in patients treated for a resectable pancreatic ductal adenocarcinoma (PA), the prognostic value of baseline CA19-9 and circulating tumour DNA (ctDNA) for overall survival (OS), to improve death risk stratification, based on a planned ancillary study from PANACHE01-PRODIGE 48 trial.